Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harbeck

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2010
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapyN Harbeck, M S Ewer, M De Laurentiis, et al.
Breast Cancer Research and Treatment|January 1, 1993
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerF Jänicke, M Schmitt, L Pache, et al.
Breast (Edinburgh, Scotland)|December 30, 2014
Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer RegistryT Kolben, N Harbeck, R Wuerstlein, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2017
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)M J Duffy, N Harbeck, M Nap, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 1999
Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitroN DePaola, P F Davies, W F Pritchard, et al.
Onkologie|July 17, 2001
Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factorN Harbeck, A Krüger, S Sinz, et al.
Gynecologic Oncology|September 14, 2010
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudyD G Kieback, N Harbeck, W Bauer, et al.
Acta Medica Austriaca. Supplement|January 1, 2003
[Tumor biology of primary breast cancer and minimal residual disease]C Schindlbeck, W Janni, P Schaffer, et al.
Radiation Oncology (London, England)|October 28, 2016
Treatment planning and evaluation of gated radiotherapy in left-sided breast cancer patients using the Catalyst<sup>TM</sup>/Sentinel<sup>TM</sup> system for deep inspiration breath-hold (DIBH)S Schönecker, F Walter, P Freislederer, et al.
British Journal of Cancer|January 1, 1997
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancerM Schmitt, C Thomssen, K Ulm, et al.
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2010
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapyN Harbeck, M S Ewer, M De Laurentiis, et al.
Breast Cancer Research and Treatment|January 1, 1993
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerF Jänicke, M Schmitt, L Pache, et al.
Breast (Edinburgh, Scotland)|December 30, 2014
Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer RegistryT Kolben, N Harbeck, R Wuerstlein, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2017
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)M J Duffy, N Harbeck, M Nap, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 1999
Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitroN DePaola, P F Davies, W F Pritchard, et al.
Onkologie|July 17, 2001
Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factorN Harbeck, A Krüger, S Sinz, et al.
Gynecologic Oncology|September 14, 2010
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudyD G Kieback, N Harbeck, W Bauer, et al.
Acta Medica Austriaca. Supplement|January 1, 2003
[Tumor biology of primary breast cancer and minimal residual disease]C Schindlbeck, W Janni, P Schaffer, et al.
Radiation Oncology (London, England)|October 28, 2016
Treatment planning and evaluation of gated radiotherapy in left-sided breast cancer patients using the Catalyst<sup>TM</sup>/Sentinel<sup>TM</sup> system for deep inspiration breath-hold (DIBH)S Schönecker, F Walter, P Freislederer, et al.
British Journal of Cancer|January 1, 1997
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancerM Schmitt, C Thomssen, K Ulm, et al.
Pageof 15